ALGS Clinical trials

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Published August 13, 2025 at 12:30 PM

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection.

Related Questions

How does the pricing and reimbursement outlook for a potential HBV cure influence the long‑term valuation of ALGS? What are the potential dilution effects from upcoming financing rounds or equity offerings to fund the trial? How will the initiation of dosing in the Phase 2 B‑SUPREME study affect ALGS’s stock price in the short‑term and medium‑term? What are the primary and secondary endpoints of the B‑SUPREME study and how do they compare to endpoints in competing HBV programs? What is the size of the addressable market for a functional cure in chronic HBV and how much market share could ALG‑000184 realistically capture? How does ALG‑000184’s mechanism of action and efficacy profile compare with other late‑stage HBV candidates (e.g., from Gilead, Novartis, Merck, etc.)? What are the key risks and uncertainties (e.g., safety signals, enrollment hurdles) that could delay or derail the Phase 2 program? What is the expected timeline for enrollment, interim data readout, and final results from the B‑SUPREME trial? What are the regulatory pathways and expected timelines for FDA/EMA approval if the Phase 2 results are positive? Will the Phase 2 data trigger any partnership, licensing, or co‑development agreements with larger pharma companies? How will the upcoming data release impact analyst coverage and consensus estimates for ALGS? What is the company’s cash runway and financing plan to fund the Phase 2 trial and subsequent development stages? Will the trial’s design (e.g., patient selection, dosing regimen) affect the likelihood of achieving a functional cure versus viral suppression? How might this trial affect the valuation of peer companies with HBV pipelines (e.g., Inovio, Virion, Gilead)? What catalysts (e.g., interim data releases, regulatory milestones) should traders monitor for short‑term trading opportunities?